Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
L Zhang, Z Qian, Z Cai, L Sun, H Wang… - American journal of …, 2009 - Wiley Online Library
Rituximab (RTX), a chimeric anti‐CD20 antibody, is associated with direct induction of
apoptosis and antibody‐dependent cell‐mediated cytotoxicity (ADCC) with clinical efficacy in …
apoptosis and antibody‐dependent cell‐mediated cytotoxicity (ADCC) with clinical efficacy in …
APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations
…, S Meng, X Han, C Sun, H Shen, L Li, L Qiu, Z Qian… - Leukemia, 2022 - nature.com
TP53 mutations correlate with inferior survival in many cancers. APR-246 is a compound to
shift mutant p53 and exhibits anti-cancer effects. Among its effects, APR-246 facilitates the …
shift mutant p53 and exhibits anti-cancer effects. Among its effects, APR-246 facilitates the …
Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative …
P Zhao, Y Xu, W Ji, S Zhou, L Li, L Qiu, Z Qian… - Journal of …, 2021 - Springer
Background Triple-negative breast cancer (TNBC) is a highly aggressive malignant disease
with a high rate of recurrence and metastasis, few effective treatment options and poor …
with a high rate of recurrence and metastasis, few effective treatment options and poor …
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
Background Ursolic acid is a promising anticancer agent. The current study aims to evaluate
the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid …
the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid …
Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors
XH Wang, SY Zhou, ZZ Qian, HL Zhang… - Expert opinion on …, 2013 - Taylor & Francis
Objective: The purpose of this study was to investigate the maximum tolerated dose (MTD),
dose-limiting toxicity (DLT), and pharmacokinetics of ursolic acid liposomes (UAL), as a new …
dose-limiting toxicity (DLT), and pharmacokinetics of ursolic acid liposomes (UAL), as a new …
[HTML][HTML] A phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors
Z Qian, X Wang, Z Song, H Zhang, S Zhou… - BioMed research …, 2015 - hindawi.com
Ursolic acid liposome (UAL), a new antitumor drug, has potential therapeutic value. However,
limited clinical data exists regarding multiple-dose safety, antitumor activity, and the …
limited clinical data exists regarding multiple-dose safety, antitumor activity, and the …
[HTML][HTML] Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR …
…, H Lv, W Li, Z Song, L Li, S Zhou, L Qiu, Z Qian… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) engagement usually
leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor …
leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor …
Cancer cell membrane camouflaged mesoporous silica nanoparticles combined with immune checkpoint blockade for regulating tumor microenvironment and …
P Zhao, L Qiu, S Zhou, L Li, Z Qian… - International Journal of …, 2021 - Taylor & Francis
Purpose Although anti-programmed cell death protein 1 antibody (aPD1) immunotherapy
and chemotherapy has made much progress in the treatment of melanoma, the efficacy still …
and chemotherapy has made much progress in the treatment of melanoma, the efficacy still …
Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
…, J Mu, Q Li, Y Pu, Y Jiang, Q Deng, Z Qian - Cancer …, 2021 - Wiley Online Library
The efficacy and side effects of the second‐time humanized CD19 chimeric antigen receptor
(CD19‐CAR) T‐cell therapy after unsuccessful first‐time anti‐CD19‐CAR T‐cell therapy …
(CD19‐CAR) T‐cell therapy after unsuccessful first‐time anti‐CD19‐CAR T‐cell therapy …
Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma
…, S Zhou, M Yu, X Wang, K Fu, Z Qian… - Leukemia & …, 2013 - Taylor & Francis
Relatively little information is available on quantitative risks of therapy-induced second
malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case–…
malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case–…
